Microsoft word - kovacsbiosketch.doc

Principal Investigator/Program Director (Last, First, Middle): BIOGRAPHICAL SKETCH
Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2. Follow this format for each person. DO NOT EXCEED FOUR PAGES.
eRA COMMONS USER NAME EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)
A. Positions and Honors.
Positions and Employment
1977-1978
Medical Internship, Royal Victoria Hospital, Montreal, Canada Second and Third Year Medical Residency, Royal Victoria Hospital Montreal, Canada Fellowship, Gastroenterology, McGil University Combined Gastro Training Program Chief Medical Resident, Royal Victoria Hospital, Montreal, Canada Research Associate, CURE, UCLA, Los Angeles, CA Adjunct Assist Professor Medicine, Gastroenterology Division, UCLA School of Medicine Director, Screening Endoscopy Program, UCLA Medical Center, Los Angeles, CA CURE-Hemostasis Research Group, Los Angeles, CA Director, Center for Ulcer Research Education (CURE) Peptic Ulcer Clinic Attending Physician-West Los Angeles VA Healthcare Center Adjunct Assoc Professor of Medicine, Gastroenterology Division, UCLA School of Medicine Adjunct Professor of Medicine, Gastroenterology Division, UCLA School of Medicine Professor of Medicine, Gastroenterology Division, UCLA School of Medicine
Other Experience and Professional Memberships
Honors and Awards

B. Total publications.
Selected peer-reviewed publications (in chronological order). Do not include publications submitted or in
preparation.
1. Steinbrecher U, Kovacs TOG, Gelly A, Tourigny M. Alanine aminotransferase level in blood units from
donors in Montreal does not indicate high risk of transmitting hepatitis. Clinical and Investigative Medicine 6:327-330, 1983. 2. Mogard MG, Maxwell V, Kovacs TOG, Van Deventer G, Elashoff JD, Yamada T, Kaufman GL, Jr. and Walsh, JH. Somatostatin inhibits gastric acid secretion after gastric mucosal prostaglandin synthesis inhibition by indomethacin in man. GUT, 26:1189-91, 1985. 3. Bunnett NW, Clark B, Debas HT, Kovacs TOG, Orloff MS, Pappas TN, Reeve JR, Jr., Rivier JE, and Walsh JH. Canine bombesin-like gastrin releasing peptides stimulate gastrin release and acid secretion in the dog. J of Physiology, 365:121-130, 1985. 4. Kovacs TOG, Van Deventer GM, Maxwell V, Sytnik B, and Walsh JH. The effect of an oral evening dose of nizatidine on nocturnal and peptone-stimulated gastric acid and gastrin secretion. Scand J of Gastroenterol, 22: (Supp 136) 41-46, 1987. Biographical Sketch Format Page
Principal Investigator/Program Director (Last, First, Middle): 5. Kovacs TOG, Mulshine JL, Cuttitta F, Maxwell V, Walsh JH. "The effects of immunoneutralization of bombesin on gastric function in dogs." In Bombesin-like Peptides in health and Disease. Tache Y, Melchiorri P, Negri L, Eds., Ann NY Acad Sci, 547:509-10, 1988. 6. Walsh JH, Kovacs TOG, Maxwell V, Cuttitta F. Bombesin-like peptides as regulators of gastric function. In Bombesin-like Peptides in Health and Disease. Tache Y, Melchiorri P, Negri L, Eds., Ann NY Acad Sci, 547:217-24, 1988. 7. Kovacs, TOG, Walsh JH, Maxwell V, Wong HC, Azuma T, Katt E. Gastrin mediates the gastric phase of canine acid secretion: Proof by monoclonal antibody immunoneutralization. Gastroenterology 97:1406-13, 1989. 8. Avis I, Kovacs TOG, Kasprzyk PG, Treston AM, Bartholomew R, Walsh JH, Cuttitta F, Mulshine J. Preclinical evaluation of an anti-growth factor monoclonal antibody to treat patients with lung cancer. J National Cancer Institute. 83:1470-761, 1991. Eysselein VE, Kovacs TOG, Kleibuker JH, Maxwell V, Reedy T, Walsh JH. Regulation of gastric acid secretion by gastrin in duodenal ulcer patients and healthy subjects. Gastroenterology 102:1142-48, 1992. 10. Lloyd KCK, Maxwell V, Kovacs TOG, Miller J, Walsh JH. Cholecystokinin receptor antagonist MK-329 blocks intestinal fat-induced inhibition of meal-stimulated gastric acid secretion. Gastroenterology 102:131-38, 1992. 11. Tarnasky PR, Kovacs TOG, Sytnik B, Walsh JH. Helicobacter pylori infection impairs pH inhibition of meal-stimulated gastrin and acid secretion in asymptomatic subjects. Digestive Dis. Sci. 38:1681-87, 1993. 12. Murphy MG, Sytnik B, Kovacs TOG, Mertz H, Ewanik D, Shingo S, Lin JH, Gertz BJ, Walsh JH. The gastrin-receptor antagonist L-365,260 inhibits stimulated acid secretion in humans. Clin Pharmacol Ther. 54: 533-39, 1993. 13. Robinson M, Decktor D, Maton, P, Sabesin, S, Roufail W, Kogut D, Roberts W, McCullough A, Pardoll P, Saco L, Rustgi V, Kovacs TOG. Omeprazole is superior to ranitidine plus metoclopramide in the short-term treatment of erosive esophagitis. Aliment Pharmacol Ther. 7:67-73, 1993. 14. Tarnasky PR, Kovacs TOG, Hirabayashi K, Leung FW, Jensen DM. Octreotide and vasopressin effects on canine gastric mucosal blood flow: controlled comparison by endoscopic reflectance spectrophotometry. Gastrointestinal Endoscopy 40:56-61, 1994. 15. Jensen DM, Cheng S, Kovacs TOG, Randall G, Jensen ME, Reedy T, Frankl H, Machicado G, Smith J, Silpa M, Van Deventer G. Randomized controlled study of ranitidine maintenance for preventing recurrent duodenal ulcer hemorrhage. New England Journal of Medicine 330:382-86, 1994. 16. Kovacs TOG, Lloyd KCK, Wong H, Walsh JH. Inhibition of bombesin-stimulated acid secretion by immunoneutralization of gastrin in dogs. American Journal of Physiology, 268 (Gastrointest.Liver Physiol. 31): G 54-58, 1995. 17. Kovacs TOG, Lloyd KCK, Walsh JH. Gastrin partially mediates insulin-induced acid secretion in dogs. 18. Savides TJ, Jensen DM, Cohen J, Randall GM, Kovacs TOG, Pelayo E, Cheng S, Jensen ME, Hsieh H. Severe upper gastrointestinal tumor bleeding: Endoscopic findings, treatment and outcome. Endoscopy 28:244-248, 1996. 19. Kovacs TOG, Decktor D, Ohning G, Eckert J, Walsh JH. The action of low dose famotidine versus therapeutic doses of cimetidine and ranitidine on human gastric acid secretion as titrated by sodium hydroxide: a placebo-controlled study. Pract Gastroenterol 20:55-59, 1996 20. Kovacs TOG, Lloyd KCK, Lawson DC, Pappas TN, Walsh JH. Inhibition of sham-feeding stimulated acid secretion in dogs by immunoneutralization of gastrin. American Journal Physiology 273 (Gastrointest. Liver Physiol. 36): G399-G403; 1997 21. Fass R, Landau O, Kovacs TOG, Ippoliti A. Esophageal motility abnormalities in cirrhotic patients after endoscopic variceal treatment. Am J Gastroenterol 92:941-946, 1997. 22. Gralnek IM, Jensen DM, Kovacs TOG, Jutabha R, Jensen ME, Cheng S, Gornbein J, Smith J. An economic analysis of patients with active arterial peptic ulcer hemorrhage treated with endoscopic heater probe, injection sclerosis or surgery in a prospective, randomized trial. Gastrointestinal Endosc 46:105-112, 1997. Continuation Format Page
Principal Investigator/Program Director (Last, First, Middle): 23. Kovacs TOG, Campbell D, Haber M, Rose P, Jennings DE, Richter J. Double-blind comparison of lansoprazole 15 mg, lansoprazole 30 mg and placebo in the maintenance of healed gastric ulcer. Digestive Dis. Sci. 43:779-85, 1998. 24. Fennerty M, Kovacs TOG, Krause R, Haber M, Weissfeld A, Siepman N, Rose P. A comparison of 10 and 14 days of lansoprazole triple therapy for eradication of Helicobacter pylori. Arch. Intern. Med. 158:1651-56, 1998. 25. Mertz H, Kovacs T, Thronson M, Weinstein W. Gastric metaplasia of the duodenum: Identification by an endoscopic selective mucosal staining technique. Gastrointestinal Endosc. 48:32-8, 1998. 26. Lew EA, Barbuti RC, Kovacs TOG, Sytnik B, Humphries TJ, Walsh JH. An ascending single-dose and tolerance study of an oral formulation of rabeprazole (E 3810). Aliment Pharm Ther 12:667-72, 1998. 27. Gralnek IM, Jensen DM, Gornbein J, Kovacs TOG, Jutabha R, Freeman ML, King J, Jensen ME, Cheng S, Machicado GA. Clinical and economic outcomes of individuals with severe peptic ulcer hemorrhage and non-bleeding visible vessel. An analysis of two consecutive prospective randomized trials. Am J Gastroenterol 93:2047-2056, 1998. 28. Kovacs TOG, Campbell D, Richter J, Haber M, Jennings DE, Rose P. Double-blind comparison of lansoprazole 15 mg, lansoprazole 30mg and placebo as maintenance theray in patients with healed duodenal ulcers resistant to H2-antagonists. Aliment Pharmacol Ther 13:959-967,1999 29. Richter JE, Kovacs TOG, Greski-Rose PA, Huang B, Fisher R. Lansoprazole in the treatment of heartburn in patients without erosive esophagitis. Aliment Pharm Ther 13:795-804, 1999. 30. Gralnek IM, Jensen DM, Kovacs TOG, Jutabha R, Machicado GA, Gorbein J, King J, Cheng S, Jensen ME. The economic impact of esophageal variceal hemorrhage: cost-effectiveness implications of endoscopic therapy. Hepatology 29:44-50, 1999. 31. Jensen DM, Machicado GA, Jutabha R, Kovacs TOG. Urgent colonoscopy for the diagnosis and treatment of severe diverticular hemorrhage. N Engl J Med 342:78-82, 2000. 32. Ohning GV, Barbuti RC, Kovacs TOG, Sytnik B, Humphries TJ, Walsh JH. Rabeprazole provides rapid, potent, and long-lasting inhibition of gastric acid secretion in subjects with Helicobacter pylori infection. Aliment Pharmacol Ther 14:701-708, 2000. 33. Fass R, Murthy U, Malagon IB, Pulliam G, Wendel C, Kovacs TOG. Omeprazole 40 mg once a day is equally effective as lansoprazole 30 mg twice a day in symptom control of patients with gastroesophageal reflux disease (GERD) – a prospective, randomized, multi-center study. Aliment Pharmacol Ther 14:1595-1603, 2000. 34. Vakil NB, Shaker R, Johnson DA, Kovacs TOG, Baerg RD, Hwang C, D’Amico D, Hamelin B. The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive esophagitis. Alimentary Pharmacology and Therapeutics 15:927-35; 2001. 35. Richter JE, Kahrilhas PJ, Sontag SJ, Kovacs TOG, Huang B, Pencyla JL. Onset of heartburn relief comparing lansoprazole with omeprazole: results of a randomized controlled trial in erosive esophagitis patients. Am J Gastroenterol 96:656-65, 2001. 36. Jensen DM, Kovacs TOG, Jutabha R, Machicado GA, Gralnek IM, Savides TJ, Smith J, Jensen ME, Alofaituli G, Gornbein J. Randomized trial of medical or endoscopic therapy to prevent recurrent ulcer hemorrhage in patients with adherent clots. Gastroenterology 123:407-413; 2002. 37. Kovacs, T.O.G., Wilcox C.M., Devoult K, Miskas D, Bochenek W. Comparison of the efficacy of pantoprazole vs. nizatidine in the treatment of erosive oesophagitis: a randomized, active-controlled, double-blind study. Aliment Pharmacol Ther 16:2043-2052, 2002. 38. Kanval F, Dulai G, Jensen DM, Gralnek I, Kovacs TOG, Machicado GA, Jutabha R. Major stigmata of recent hemorrhage on rectal ulcers in patients with severe hematochezia: endoscopic diagnosis, treatment and outcomes. Gastrointestinal Endoscopy 55:AB122, 2002. 39. Ohning GV, Walsh JH, Pisegna JR, Murthy A, Barth J, Kovacs TOG. Rabeprazole is superior to omeprazole for the inhibition of peptone meal-stimulated gastric acid secretion in Helicobacter pylori-negative subjects. Aliment Pharmacol Ther 17:1109-1114, 2003. 40. Dulai GS, Jensen DM, Kovacs TOG, Jutabha R, Gralnek IM. Endoscopic treatment outcomes in Watermelon Stomach patients with and without portal hypertension. Endoscopy 36:1-5; 2004 Continuation Format Page
Principal Investigator/Program Director (Last, First, Middle): C. Research Support. List selected ongoing or completed (during the last three years) research projects (federal and non-federal
support). Begin with the projects that are most relevant to the research proposed in this application. Briefly indicate the overall goals
of the projects and your role (e.g. PI, Co-Investigator, Consultant) in the research project. Do not list award amounts or percent effort
in projects.
Ongoing Research Support
Completed Research Support

Continuation Format Page

Source: http://www.cure.med.ucla.edu/sites/default/files/members/biosketch/tkovacs.pdf